Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries

Bahira Shahim, Björn Redfors, Brian R Lindman, Shmuel Chen, Torsten Dahlen, Tamim Nazif, Samir Kapadia, Zachary M Gertz, Aaron C Crowley, Ditian Li, Vinod H Thourani, Susheel K Kodali, Alan Zajarias, Vasilis C Babaliaros, Robert A Guyton, Sammy Elmariah, Howard C Herrmann, David J Cohen, Michael J Mack, Craig R Smith, Martin B Leon, Isaac George, Bahira Shahim, Björn Redfors, Brian R Lindman, Shmuel Chen, Torsten Dahlen, Tamim Nazif, Samir Kapadia, Zachary M Gertz, Aaron C Crowley, Ditian Li, Vinod H Thourani, Susheel K Kodali, Alan Zajarias, Vasilis C Babaliaros, Robert A Guyton, Sammy Elmariah, Howard C Herrmann, David J Cohen, Michael J Mack, Craig R Smith, Martin B Leon, Isaac George

Abstract

Background The neutrophil-to-lymphocyte ratio (NLR) as a marker of systemic inflammation has been associated with worse prognosis in several chronic disease states, including heart failure. However, few data exist on the prognostic impact of elevated baseline NLR or change in NLR levels during follow-up in patients undergoing transcatheter or surgical aortic valve replacement (TAVR or SAVR) for aortic stenosis. Methods and Results NLR was available in 5881 patients with severe aortic stenosis receiving TAVR or SAVR in PARTNER (Placement of Aortic Transcatheter Valves) I, II, and S3 trials/registries (median [Q1, Q3] NLR, 3.30 [2.40, 4.90]); mean NLR, 4.10; range, 0.5-24.9) and was evaluated as continuous variable and categorical tertiles (low: NLR ≤2.70, n=1963; intermediate: NLR 2.70-4.20, n=1958; high: NLR ≥4.20, n=1960). No patients had known baseline infection. High baseline NLR was associated with increased risk of death or rehospitalization at 3 years (58.4% versus 41.0%; adjusted hazard ratio [aHR], 1.39; 95% CI, 1.18-1.63; P<0.0001) compared with those with low NLR, irrespective of treatment modality. In both patients treated with TAVR and patients treated with SAVR, NLR decreased between baseline and 2 years. A 1-unit observed decrease in NLR between baseline and 1 year was associated with lower risk of death or rehospitalization between 1 year and 3 years (aHR, 0.86; 95% CI, 0.82-0.89; P<0.0001). Conclusions Elevated baseline NLR was independently associated with increased subsequent mortality and rehospitalization after TAVR or SAVR. The observed decrease in NLR after TAVR or SAVR was associated with improved outcomes. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT00530894, NCT0134313, NCT02184442, NCT03225001, NCT0322141.

Keywords: NLR; aortic stenosis; neutrophil‐to‐lymphocyte ratio; surgical aortic valve replacement; transcatheter aortic valve replacement.

Figures

Figure 1. Kaplan–Meier time‐to‐first‐event analyses by tertiles…
Figure 1. Kaplan–Meier time‐to‐first‐event analyses by tertiles of neutrophil‐to‐lymphocyte ratio in patients undergoing transcatheter aortic valve replacement or surgical aortic valve replacement.
(A) Death or rehospitalization; (B) death; (C) rehospitalization. HR indicates hazard ratio; and NLR, neutrophil‐to‐lymphocyte ratio.
Figure 2. Kaplan‐Meier time‐to‐first‐event analyses by tertiles…
Figure 2. Kaplan‐Meier time‐to‐first‐event analyses by tertiles of neutrophil‐to‐lymphocyte ratio in patients undergoing transcatheter aortic valve replacement or surgical aortic valve replacement.
(A) Death or rehospitalization; (B) death; (C) rehospitalization. HR indicates hazard ratio; and NLR, neutrophil‐to‐lymphocyte ratio.

References

    1. Jahng JW, Song E, Sweeney G. Crosstalk between the heart and peripheral organs in heart failure. Exp Mol Med. 2016;48:e217. doi: 10.1038/emm.2016.20
    1. Van Linthout S, Tschope C. Inflammation – cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017;14:251–265. doi: 10.1007/s11897-017-0337-9
    1. Pandey A, Kitzman D, Reeves G. Frailty is intertwined with heart failure: mechanisms, prevalence, prognosis, assessment, and management. JACC Heart Fail. 2019;7:1001–1011. doi: 10.1016/j.jchf.2019.10.005
    1. Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, Meghani M, Akhtar M, Costantino T. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11:55–59. doi: 10.1586/erc.12.159
    1. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB. Intermountain Heart Collaborative Study G . Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45:1638–1643. doi: 10.1016/j.jacc.2005.02.054
    1. Templeton AJ, McNamara MG, Šeruga B, Vera‐Badillo FE, Aneja P, Ocaña A, Leibowitz‐Amit R, Sonpavde G, Knox JJ, Tran B, et al. Prognostic role of neutrophil‐to‐lymphocyte ratio in solid tumors: a systematic review and meta‐analysis. J Natl Cancer Inst. 2014;106:dju124. doi: 10.1093/jnci/dju124
    1. Delcea C, Buzea CA, Dan GA. The neutrophil to lymphocyte ratio in heart failure: a comprehensive review. Rom J Intern Med. 2019;57:296–314. doi: 10.2478/rjim-2019-0018
    1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, et al. Transcatheter aortic‐valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607. doi: 10.1056/NEJMoa1008232
    1. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, et al. Transcatheter or surgical aortic‐valve replacement in intermediate‐risk patients. N Engl J Med. 2016;374:1609–1620. doi: 10.1056/NEJMoa1514616
    1. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, et al. Transcatheter versus surgical aortic‐valve replacement in high‐risk patients. N Engl J Med. 2011;364:2187–2198. doi: 10.1056/NEJMoa1103510
    1. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, Smalling R, Lim S, Malaisrie SC, Kapadia S, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate‐risk patients: a propensity score analysis. Lancet (London, England). 2016;387:2218–2225. doi: 10.1016/s0140-6736(16)30073-3
    1. Eilers PHCM, Brian D. Flexible smoothing with B ‐splines and penalties. Sci. 1996;11:89–121. doi: 10.1214/ss/1038425655
    1. Dafni U. Landmark analysis at the 25‐year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4:363–371. doi: 10.1161/CIRCOUTCOMES.110.957951
    1. Cho KI, Cho SH, Her AY, Singh GB, Shin ES. Prognostic utility of neutrophil‐to‐lymphocyte ratio on adverse clinical outcomes in patients with severe calcific aortic stenosis. PLoS One. 2016;11:e0161530. doi: 10.1371/journal.pone.0161530
    1. Habib M, Thawabi M, Hawatmeh A, Habib H, ElKhalili W, Shamoon F, Zaher M. Value of neutrophil to lymphocyte ratio as a predictor of mortality in patients undergoing aortic valve replacement. Cardiovasc Diagn Ther. 2018;8:164–172. doi: 10.21037/cdt.2018.03.01
    1. Khalil C, Pham M, Sawant AC, Sinibaldi E, Bhardwaj A, Ramanan T, Qureshi R, Khan S, Ibrahim A, Gowda SN, et al. Neutrophil‐to‐lymphocyte ratio predicts heart failure readmissions and outcomes in patients undergoing transcatheter aortic valve replacement. Indian Heart J. 2018;70:S313–S318. doi: 10.1016/j.ihj.2018.08.002
    1. Condado JF, Junpaparp P, Binongo JN, Lasanajak YI, Witzke‐Sanz CF, Devireddy C, Leshnower B, Mavromatis K, Stewart J, Guyton R, et al. Neutrophil‐lymphocyte ratio (NLR) and platelet‐lymphocyte ratio (PLR) can risk stratify patients in transcatheter aortic‐valve replacement (TAVR). Int J Cardiol. 2016;223:444–449. doi: 10.1016/j.ijcard.2016.08.260
    1. Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail. 2017;19:1379–1389. doi: 10.1002/ejhf.942
    1. Vemulapalli S, Dai D, Hammill BG, Baron SJ, Cohen DJ, Mack MJ, Holmes DR Jr. Hospital resource utilization before and after transcatheter aortic valve replacement: the STS/ACC TVT registry. J Am Coll Cardiol. 2019;73:1135–1146. doi: 10.1016/j.jacc.2018.12.049
    1. Inohara T, Manandhar P, Kosinski AS, Matsouaka RA, Kohsaka S, Mentz RJ, Thourani VH, Carroll JD, Kirtane AJ, Bavaria JE, et al. Association of renin‐angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA. 2018;320:2231–2241. doi: 10.1001/jama.2018.18077
    1. Rodriguez‐Gabella T, Catala P, Munoz‐Garcia AJ, Nombela‐Franco L, Del Valle R, Gutierrez E, Regueiro A, Jimenez‐Diaz VA, Ribeiro HB, Rivero F, et al. Renin‐angiotensin system inhibition following transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74:631–641. doi: 10.1016/j.jacc.2019.05.055
    1. Amat‐Santos IJ, Catalá P, Diez del Hoyo F, Fernandez‐Diaz JA, Alonso‐Briales JH, Del Trigo M, Regueiro A, Juan‐Salvadores P, Serra V, Gutierrez‐Ibanes E, et al. Impact of renin‐angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study. BMJ Open. 2018;8:e020255. doi: 10.1136/bmjopen-2017-020255
    1. Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, Rihal CS, Zajarias A, Doshi D, Davidson M, et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J. 2015;36:449–456. doi: 10.1093/eurheartj/ehu384

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅